Amniotic membrane transplantation for Stevens-Johnson syndrome/toxic epidermal necrolysis: Review of adult and paediatric cases in Toronto
My Session Status
Authors: Yelin Yang, Hall Chew, Kamiar Mireskandari, Simon Fung,
Asim Ali
Author Disclosure Block: Y. Yang: None. H. Chew: None. K.
Mireskandari: Membership on advisory boards or speakers’ bureaus;
Santen Inc. S. Fung: None. A. Ali: Membership
on advisory boards or speakers’ bureaus; Santen Inc.
Abstract Body:
Purpose: In patients with Stevens-Johnson syndrome (SJS)
/toxic epidermal necrolysis (TEN), the ocular surface is markedly inflamed in
the acute setting which can lead to significant long-term sequelae. Early use
of amniotic membrane transplantation (AMT) suppresses inflammation and promotes
healing in these patients. This study aims to review the Toronto experience of
AMT among patients with acute ocular SJS/TEN.
Study Design: Multicentre consecutive case series
Methods: Patients who underwent AMT for ocular SJS/TEN at the
Hospital for Sick Children and Sunnybrook Health Sciences Centre between 2010
and 2018 were included in the study. Outcomes and clinical data including
best-corrected visual acuity (BCVA), ocular surface and lid abnormalities
including trichiasis, distichiasis, lid keratinization, tarsal scarring,
entropion, symblepharon, superficial punctal keratitis/epithelial defect and
limbal stem cell deficiency (LSCD) were analyzed.
Results: Thirty-two eyes of 16 patients (9 adult, 7 paediatric)
were included in the study with median follow up of 33 months (range 4 months
to 9 years). Of these patients, 62% (10/16) were male and the mean age was 24.4
years. The median number of days between diagnosis and AMT was 3 (range 1 to
30), where 14 patients received AMT within 7 days of diagnosis. Preoperatively,
BCVA was worse than 20/200 in 8/16 eyes with available data. The majority of
patients had severe ocular involvement, including conjunctival injection (32/32
eyes), corneal epithelial defect (26/32) symblepharon formation (24/32) and
pseudomembranous conjunctivitis (20/32). Complications, and the median time to
the complication, were as follows: lid margin keratinization (26/32, 3 months),
symblepharon (18/32, 1.5 month), tarsal conjunctival scarring (16/32, 2
months), trichiasis (12/32, 2 months), distichiasis (9/32, 10 months), lid
entropion (7/32, 3 months) and LSCD (7/32, 5 months). All adult patients had
evidence of lid keratinization, while pediatric patients had proportionally
higher rate of entropion (7 eyes) and LSCD (5 eyes). At last follow up, 21/32
of eyes had BCVA ≥20/40, while vision in the remaining 11 eyes was limited
mostly due to corneal scarring,LSCD or poor compliance with treatment. Two
patients that had delayed AMT at 13 and 30 days respectively had poorer visual
outcome and developed significant LSCD. Three patients in the pediatric group
required entropion repair within the first year.
Conclusions: AMT is an effective treatment for stabilizing the
ocular surface during the acute phase of SJS/TEN. However, chronic ocular
sequelae can still occur in long term and require close monitoring.